ABSTRACT
Results:
Pathologists' most relevant recommendation: "Do not transfuse more units of blood than absolutely necessary"; highest priority: "Do not transfuse more than the minimum number of RBC units necessary to relieve symptoms of anemia or to return a patient to a safe hemoglobin range (7) (8) 
g/dL in stable, noncardiac inpatients)." Laboratory professionals' most relevant recommendation: "Avoid testing for a Clostridium difficile infection in the absence of diarrhea"; highest priority: "Do not routinely transfuse stable, asymptomatic hospitalized patients with a hemoglobin level greater than 7 to 8 g/dL."

Conclusions: Most of the highest priority, most relevant recommendations among those surveyed concerned utilization of blood products and transfusion management.
In 2012, the American Board of Internal Medicine (ABIM) Foundation launched the Choosing Wisely campaign to create and advance a "national dialogue on avoiding wasteful or unnecessary medical tests, treatments, and procedures." 1 The American Society for Clinical Pathology (ASCP) was invited to join the campaign as the representative of pathology and laboratory medicine. Over the ensuing 5 years, more than 75 specialty society partners have released nearly 500 recommendations to facilitate decisions by patients and providers about appropriate care and utilization of medical services. Although ASCP is the only general pathology organization participating in the Choosing Wisely campaign, many other specialty societies have put forth recommendations that are pertinent to the practice of laboratory medicine. The laboratory team plays a critical leadership role in promoting and managing the delivery and use of health care resources-and initiating conversations regarding appropriate care with clinicians and patients. As part of its ongoing efforts to support patient-centered care and evidence-based medicine, ASCP conducted a survey to prioritize Choosing Wisely recommendations developed by non-ASCP participating organizations to determine the most relevant ones for effective use of laboratory services, allowing ASCP to identify opportunities for collaboration with other societies to optimize laboratory utilization.
Materials and Methods
Survey Development
A survey was conducted by ASCP's Institute of Science, Technology, and Policy (Washington, DC) and Respondents who spent less than 5 minutes on the survey were excluded from analysis. The rank of each recommendation was calculated using weighted averages of the relevance to identify the most relevant recommendations for pathologists and the most relevant recommendations for laboratory professionals.
The top 50 recommendations that had the highest relevance were then presented to the same respondents for the second survey deployment (ie, for prioritization). The respondents used the prioritization scale shown in ❚Table 2❚ to prioritize the recommendations based on the five guiding principles. This list was then ranked to identify the 20 most relevant, highest-priority, non-ASCP pathology-and laboratory medicine-related Choosing Wisely recommendations for each group (eg, pathologists and laboratory professionals).
Results
Relevance Survey
The relevance survey was distributed to pathologists and laboratory professionals from the ASCP email database currently practicing in various settings. A total of 755 respondents completed the survey (295 pathologists and 460 laboratory professionals) ❚Table 3❚. Most respondents work in hospitals (academic, nonacademic, community based) and the least in nonhospital settings ❚Table 4❚. Results show that 55% of pathologists who started the survey completed it (3.6% of the pathologists receiving Table 3) .
Priority Survey
The priority survey was distributed to 256 pathologists and 377 laboratory professionals working in various practice settings ❚Table 5❚. Some respondents from the relevance survey were not included in the priority survey because 39 pathologists and 83 laboratory professionals were unemployed or retired. Most respondents work in hospitals (academic, nonacademic, community based) and the least in nonhospital settings ❚Table 6❚. Results show that 87% of pathologists who started the survey completed it (29% of the pathologists who received the survey). Of the laboratory professionals who started the survey, 90% completed it (28% of the laboratory professionals who received the survey).
Most Relevant Recommendations for Pathologists and Laboratory Professionals
The most relevant recommendations for each group are shown in ❚Table 7❚. 3 All top 10 most relevant recommendations for pathologists focused on hematology and transfusion medicine. Recognize, however, that four of the top 10 recommendations overlapped in concept, essentially representing one collective recommendation (pathologists' ranked recommendations 1, 2, 4, and 9) ( Table 7 ). The analysis was extended to the top 11 to 20 recommendations for each group because of significant overlap in concept in the top 10 recommendations.
Laboratory professionals' responses focused on either (1) lower cost tests ordered frequently (eg, repeat CBCs in stable patients) or (2) less frequently performed but costly genetic tests (eg, for inherited conditions in the absence of uncertainty about the result).
Highest Priority Recommendations for Pathologists and Laboratory Professionals
Pathologists and laboratory professional priority rankings are shown in ❚Table 8❚.
3
Discussion
Blood Product Management
Blood product management is high priority and relevant for pathologists and laboratory professionals 
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Patient blood management is a priority for pathologists for several reasons-patient safety, reducing transfusion associated risk, established and emerging recommendations for transfusion and handling anemia, and Avoid testing for a Clostridium difficile infection in the absence of diarrhea. 11 1 Do not order diagnostic tests (arterial blood gases, blood chemistries, blood counts) at regular intervals (such as every day) but rather in response to specific clinical questions.
6
Do not transfuse O-negative blood except to O-negative patients and in emergencies for women of childbearing potential with unknown blood group.
18
Do not use antibiotics in patients with recent C difficile without convincing evidence of need. Antibiotics pose a high risk of C difficile recurrence.
14 4
Do not administer packed RBCs in a young healthy patient without ongoing blood loss and hemoglobin of 6 g/dL or greater unless symptomatic hemodynamically unstable.
17
Do not obtain a C difficile toxin test to confirm "cure" if symptoms have resolved. 16 7 Avoid the use of surveillance cultures for the screening and treatment of asymptomatic bacteruria.
10
Do not administer plasma or prothrombin complex concentrates for nonemergent reversal of vitamin K antagonists (ie, outside of the setting of major bleeding, intracranial hemorrhage, or anticipated emergent surgery).
-
Do not transfuse RBCs for iron deficiency without hemodynamic instability. 8 -Do not routinely use blood products to reverse warfarin. 10 -Do not order exome or genome sequencing before obtaining informed consent that includes the possibility of secondary findings.
Do not order a duplicate genetic test for an inherited condition unless there is uncertainty about the validity of the existing test result.
In patients with low pretest probability of venous thromboembolism, obtain a highsensitive D-dimer measurement as the initial diagnostic test; do not obtain imaging studies as the initial diagnostic test.
Do not obtain a urine culture unless there are clear signs and symptoms that localize to the urinary tract.
-3
Do not routinely measure 1,25-dihydroxyvitamine D unless the patient has hypocalcemia or decreased kidney function.
-9
Do not order a total or free T3 level when assessing levothyroxine (T4) dose in hypothyroid patients.
-12
Offer PSA screening for detecting prostate cancer only after engaging in shared decision making.
-16
Do not repeat hepatitis C viral load testing (highly sensitive quantitative hepatitis C RNA assays) outside of antiviral therapy.
-19
Do not order autoantibody panels unless positive antinuclear antibodies and evidence of rheumatic disease. Do not transfuse more than the minimum number of RBC units necessary to relieve symptoms of anemia or to return a patient to a safe hemoglobin range (7-8 g/dL in stable, noncardiac, inpatients).
9
Do not transfuse more units of blood than absolutely necessary. 2 2 Do not routinely transfuse stable, asymptomatic hospitalized patients with a hemoglobin level greater than 7 to 8 g/dL.
3 1
Avoid transfusions of RBCs for arbitrary hemoglobin or hematocrit thresholds and in the absence of symptoms of active coronary disease, heart failure, or stroke.
11
Do not perform serial blood counts on clinically stable patients. 7 15 Do not routinely transfuse fresh-frozen plasma and platelets prior to abdominal paracentesis or endoscopic variceal band ligation.
6
Do not transfuse RBCs for iron deficiency without hemodynamic instability. 9 3 Do not order diagnostic tests (arterial blood gases, blood chemistries, blood counts) at regular intervals (such as every day) but rather in response to specific clinical questions.
5
Do not routinely use blood products to reverse warfarin. 14 16 Do not administer plasma or prothrombin complex concentrates for nonemergent reversal of vitamin K antagonists (ie, outside of the setting of major bleeding, intracranial hemorrhage, or anticipated emergent surgery).
20
8
Avoid testing for a Clostridium difficile infection in the absence of diarrhea. 5 -Do not perform repetitive CBC and chemistry testing in the face of clinical and laboratory stability.
-
Do not transfuse RBCs in hemodynamically stable, nonbleeding ICU patients with a hemoglobin concentration greater than 7 g/dL.
4
Do not obtain a C difficile toxin test to confirm "cure" if symptoms have resolved. 12 -Avoid the use of surveillance cultures for the screening and treatment of asymptomatic bacteruria.
-
Do not perform screening panels for food allergies without previous consideration of medical history.
Do not routinely transfuse patients with sickle cell disease for chronic anemia or uncomplicated pain crisis without appropriate clinical indication.
-7
Do not perform unproven diagnostic tests, such as IgG testing of an indiscriminate battery of IgE tests, in the evaluation of allergy.
-10
Do not order autoantibody panels unless positive antinuclear antibodies and evidence of rheumatic disease.
-13
Do not perform repetitive CBC [and chemistry] testing in the face of clinical and laboratory stability.
-14
Do not order exome or genome sequencing before obtaining informed consent that includes the possibility of secondary findings.
-18
Do not perform food IgE testing without a history consistent with potential IgE-mediated food allergy.
ICU, intensive care unit; IgE, immunoglobulin E; IgG, immunoglobulin G. data that blood tests can provide, iatrogenic anemia from repeated phlebotomy may be a concern. 6 As a result, medical and economic factors become areas of focus in many medical institutions when applying transfusion as a therapeutic modality. 6 Laboratory professionals' responses also focused on blood product management as a high priority. Increasingly, hospitals are cutting back on high-volume tests, especially those involving phlebotomy, to reduce costs while adding benefit to patients by reducing complications associated with blood draws. 4 In addition, government programs that measure patient satisfaction have placed new emphasis on the overuse of phlebotomy in the hospital setting. 7 Many Choosing Wisely recommendations developed by other organizations are relevant to the practice of pathology and laboratory medicine. Because the recommendations were developed by different organizations and in the Choosing Wisely campaign format, there is overlap among some high-priority/relevance conditions (eg, blood product/transfusion management). Areas of importance for pathologists and laboratory professionals significantly overlap. The judicious and appropriate use of blood and blood products is important for the safety and cost-effective management of patients. Inappropriate testing can lead to excessive phlebotomy and unnecessary evaluation of false-positive tests results, especially when the prior probability of disease is low.
Genetic Testing
While pathologists consider genetic testing to be relevant, it is a high priority for laboratory professionals. Since 2000, there has been an influx of new genetic diagnostic tests. Available genetic tests increase 10% annually, and genetic-based diagnostic tests increase at 20%. 8 Lack of robust regulation of these tests leads to significant variability among laboratories, both related to quality metrics for large parallel DNA panel and whole-genome sequencing, as well as computational classification of variants as benign or pathogenic. 9 Despite relatively low volumes, genetic testing panels have been a target of laboratory utilization improvement efforts due to the relatively high cost and complexities of ordering result interpretation.
10
Clostridium difficile Tests
Clostridium difficile infection (CDI) is a leading cause of hospital-associated gastrointestinal illness that frequently stresses the health care system. CDI is a national priority and is included as a measure in the Centers for Medicare & Medicaid Services' Hospital Acquired Condition Reduction Program. 6, 11 Patients with CDI typically have extended lengths of stay, and CDI causes large hospital disease outbreaks. 2 CDI is associated with significant morbidity and mortality and is a substantial pharmacoeconomic burden on institutions and society; therefore, it is crucial to appropriately identify, diagnose, and treat this infection. 4 Pathologists and laboratory professionals are well aware of the substantial benefit that can come from using tests for C difficile more effectively, including more accurate estimates of CDI incidence, reduction in unnecessary antibiotic use, and improvement of facilities' performance of reportable CDI metrics. 5 In addition, because most respondents practice in a hospital setting, heightened awareness and added pressure from hospital administration may be a factor. The high priority related to inappropriate C difficile testing also reflects concern for false-positive findings, leading to unnecessary antibiotic exposure and inappropriate public health reporting.
9
Summary
The survey results reveal much important information about the views of ASCP members regarding published recommendations produced by other organizations that relate to the laboratory field. We identified three main conclusions. First, we identified the most relevant and prioritized recommendations in pathology and laboratory medicine. Blood product management, genetic testing, and C difficile tests were highly ranked by survey respondents due to their increased potential for patient safety concerns. Laboratories are starting to put more focus on ordering practices regarding these three areas of testing. For instance, Cedars-Sinai Medical Center in Los Angeles, California, integrated resource management into practice by creating alerts in their electronic medical record to educate clinicians on transfusion medicine best practices; alerts are designed to reduce duplicative testing and test panels that include reflex testing. This approach led to improvements in transfusion medicine practice, such as reduced duplicative testing, showcasing how high-priority and relevant Choosing Wisely recommendations can be integrated into practice.
Second, survey results suggest that pathology and laboratory professionals' awareness of the most relevant and high-priority recommendations in the field equips them to become integral partners in addressing solutions in their laboratories and institutions, as well as partner with external organizations. This type of collaboration is already occurring in some large laboratories. For example, in addressing the burden of unnecessary © American Society for Clinical Pathology AJCP / Original article phlebotomy placed on patients, Gary W. Procop (medical director, Enterprise Laboratory Stewardship Utilization Committee at Cleveland Clinic) and an interdisciplinary team developed an elegant solution to same-day repeat test ordering in their institution. The team reduced sameday duplicate test ordering by blocking repeat orders of tests that the utilization committee deemed inappropriate and were vetted through the entire medical staff. This initiative was deployed in a staged manner, in association with educational efforts. A full electronic stop was placed on tests determined not to be necessary more than once per day; over 1,200 tests on the test menu met the criteria for a "hard stop." Ordering clinicians had to call the laboratory if they were still insistent on ordering tests on the hard stop list. Since the inception of this program through 2016, a total of 29,386 same-day unnecessary duplicate orders have been stopped for a cost savings of $468,107. In addition, the team garnered respect with other clinicians who began to more fully recognize their laboratory colleagues as integral members of the patient care team. 12 Last, laboratorians recognize that this is an area in which they can affect patient experience and satisfaction, and the relevance and priority recommendations they ranked most highly reflect this issue. 3 Generally, laboratorians prefer to perform testing that is meaningful and impactful for the patient; pathologists and laboratory personnel bring this perspective and diagnostic knowledge to the clinical scenario and can inform ordering clinicians that excessive testing not only unnecessarily increases the workload but also can be harmful to patients. 10 More routine/less expensive tests that are ordered much too frequently (eg, CBCs) may be ordered daily or unnecessarily for a number of reasons, such as financial incentives, physician habit, or lack of time to effectively evaluate a patient's condition, 13 or they could be ordered in response to changes in patient care protocols, such as elimination of inpatient standing orders.
Limitations
While the results of the study can apply to a broad range of pathologists and laboratory professionals practicing in a variety of settings, there are limitations. First, most respondents work in hospital settings, so more priority and relevance were placed on recommendations that pertain to work in the hospital setting. Second, the survey focused on specialties and certifications that were more represented in the ASCP email database. Third, Choosing Wisely organizations have developed recommendations based on their priorities and, to some extent, the amount of agreement within their specialty organizations. Fourth, many other recommendations from specialty societies, the government, and organizations may be of higher priority but have not been incorporated yet into the Choosing Wisely content. Fifth, this survey studied only the recommendations made through April 2016. More non-ASCP pathology-and laboratory medicine-related recommendations have been published since that time. Future studies are recommended to investigate potential shifts or changes in priorities.
Conclusions
Focusing on Choosing Wisely recommendations across disciplines should improve patient care and lower health care costs. Because there are hundreds of laboratory-related Choosing Wisely recommendations from multiple specialty organizations, there are many opportunities to foster interdisciplinary performance improvement initiatives. Pathologists and laboratory professionals are uniquely positioned to leverage their expertise and connections with multiple disciplines to improve overall utilization and health care quality. Systematic review of the ABIM's Choosing Wisely recommendations can help identify areas of overlap or consensus regarding reducing unnecessary laboratory testing and procedures. Analyzing recommendations from all organizations helps identify opportunities for collaboration to create programs for educating clinicians and influence physician and hospital policies. Because patient care is multidisciplinary, broad input from stakeholders is pertinent to advancing the goals of the Choosing Wisely campaign. This study contributed to these aims by analyzing the non-ASCP recommendations (ie, submitted by other specialty societies) to identify the top pathology-and laboratory medicinerelated recommendations that are most relevant and highest priority for effective laboratory test utilization. In addition, the survey results help to identify areas of mutual concern for various specialty groups and identify potential opportunities for broader engagement and collaboration. 
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